Clinical Trials About "POXEL S.A." RSS

13:35 EDT 18th March 2019 | BioPortfolio

We list hundreds of Clinical Trials about "POXEL S.A." on BioPortfolio. We draw our references from global clinical trials data listed on and refresh our database daily.

More Information about "POXEL S.A." on BioPortfolio

We have published hundreds of POXEL S.A. news stories on BioPortfolio along with dozens of POXEL S.A. Clinical Trials and PubMed Articles about POXEL S.A. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of POXEL S.A. Companies in our database. You can also find out about relevant POXEL S.A. Drugs and Medications on this site too.

Showing "POXEL" Clinical Trials, all 1


Safety, Tolerability and PK of PXL770 in Healthy Male Subjects

PXL770 is a direct activator of 5' adenosine monophosphate-activated protein kinase (AMPK) being developed by Poxel S.A. for the treatment of type 2 diabetes mellitus (T2DM). In Part A of this study, we'll test the safety, tolerability and pharmacokinetics (PK) of repeated doses. In Part B, we'll co-administer PXL770 and rosuvastatin (a HMG-CoA reductase inhibitor) to assess any drug-drug interaction.

More From BioPortfolio on "POXEL S.A."

Quick Search